Mepolizumab use significantly reduced the use of oral corticosteroids and substantially reduced exacerbations in patients with both allergic and non-allergic asthma. These were among the findings of a real-world study presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annuber 10 to 14, in Louisville, Kentucky.

Although the efficacy and safety of mepolizumab for treating patients with severe asthma is well-documented, investigators sought to establish the therapy’s comparative effectiveness for treating those with non-allergic and allergic asthma.

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019. Investigators identified 298 (55.4%) patients with non-allergic asthma and 240 (44.6%) patients with allergic asthma, using diagnosis codes, lab test results, and medication history to identify patients’ allergic status.


Continue Reading

This study supports the real-world effectiveness of mepolizumab for the treatment of severe asthma with allergic and non-allergic phenotypes.

The researchers analyzed patients’ oral corticosteroid (OCS) use and asthma exacerbation rate in the baseline period (12 months before mepolizumab initiation) and in the follow-up period (12 months following initiation). The analysis of exacerbations found a substantial reduction in the mean (SD) rate of asthma exacerbations from baseline to follow-up for patients with non-allergic asthma (2.51 [2.17] to 1.70 [1.92]; P <.001) and for patients with allergic asthma (3.19 [2.49] to 2.10 [2.12]; P <.001). The analysis of OCS use showed a significant reduction from baseline to follow-up in the mean (SD) count of OCS claims for patients with non-allergic asthma (5.46 [4.12] to 3.20 [3.69]; P <.001) and for patients with allergic asthma (5.19 [4.47] to 3.46 [4.50]; P <.001).

No significant differences were found in asthma exacerbation rates or counts of OCS claims from baseline to follow-up between cohorts.

“This study supports the real-world effectiveness of mepolizumab for the treatment of severe asthma with allergic and non-allergic phenotypes,” investigators concluded.

Reference

Silver J, Steffens A, Chastek B, Deb A. Real world effectiveness of mepolizumab in patients with allergic and non-allergic asthmaAnn Allergy Asthma Immunol. 2022;125(5):S42-43. doi:10.1016/j.anai.2022.08.624

This article originally appeared on Pulmonology Advisor